Literature DB >> 22838637

Investigation of the role of FcγR and FcRn in mAb distribution to the brain.

Lubna Abuqayyas1, Joseph P Balthasar.   

Abstract

To evaluate the role of Fc receptors (FcR) on IgG distribution to the brain, the disposition of 8C2, a murine monoclonal IgG1 antibody, was investigated after intravenous administration in FcRn α-chain knockout mice, FcγRIIb knockout mice, FcγRI/RIII knockout mice, and C57BL/6 control mice. (125)I-8C2 was co-administered with (51)Cr-labeled red blood cells to allow accurate assessment of residual blood content in brain samples. Blood and brain tissues were harvested from subgroups of three mice at several time-points up to 10 days, and radioactivity was counted. The blood and brain areas under 8C2 concentration vs time curves (AUCs) were calculated using the linear trapezoidal rule, and the associated standard deviations (SD) were assessed using a modified Bailer method. Concentration data were also analyzed with a semiphysiological population pharmacokinetic model. The brain/blood AUC ratios were comparable across all strains of mice (ratios ± SD): 0.00774 ± 0.000452, 0.00841 ± 0.000535, 0.00636 ± 0.000548, and 0.00917 ± 0.000478 for C57BL/6 control mice, FcγRI/RIII knockouts, FcγRIIb knockouts, and FcRn α-chain knockout mice (p > 0.05). Statistically significant improvement in model fitting of the data was shown with incorporation of a strain-specific parameter for antibody clearance for FcRn knockout mice; however, no significant improvements in model fitting were found for strain effects on any other parameter, including the brain uptake clearance or efflux clearances for 8C2. The predicted 8C2 brain efflux clearance was found to be ∼135-fold faster than the brain uptake clearance, consistent with the observed low ratio of brain-blood exposure. The experimental results and modeling results indicate that, in mice, FcRn and FcγR do not contribute to the "blood-brain barrier" that limits mAb uptake into the brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22838637     DOI: 10.1021/mp300214k

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  28 in total

1.  Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.

Authors:  Yao-Yun Fan; Lindsay B Avery; Mengmeng Wang; Denise M O'Hara; Sheldon Leung; Hendrik Neubert
Journal:  MAbs       Date:  2016-04-22       Impact factor: 5.857

2.  Antibody pharmacokinetics in rat brain determined using microdialysis.

Authors:  Hsueh-Yuan Chang; Kasey Morrow; Emily Bonacquisti; WanYing Zhang; Dhaval K Shah
Journal:  MAbs       Date:  2018-08-06       Impact factor: 5.857

Review 3.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

4.  Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.

Authors:  Thomas G Weber; Franz Osl; Anja Renner; Thomas Pöschinger; Stefanie Galbán; Alnawaz Rehemtulla; Werner Scheuer
Journal:  Cancer Res       Date:  2014-02-07       Impact factor: 12.701

5.  A translational platform PBPK model for antibody disposition in the brain.

Authors:  Hsueh-Yuan Chang; Shengjia Wu; Guy Meno-Tetang; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-21       Impact factor: 2.745

6.  Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  AAPS J       Date:  2016-03-30       Impact factor: 4.009

7.  The effect of the neonatal Fc receptor on human IgG biodistribution in mice.

Authors:  Nancy Chen; Weirong Wang; Scott Fauty; Yulin Fang; Lora Hamuro; Azher Hussain; Thomayant Prueksaritanont
Journal:  MAbs       Date:  2014-01-09       Impact factor: 5.857

8.  Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.

Authors:  Denise Karaoglu Hanzatian; Annette Schwartz; Farid Gizatullin; Jamie Erickson; Kangwen Deng; Ruth Villanueva; Christopher Stedman; Cristina Harris; Tariq Ghayur; Andrew Goodearl
Journal:  MAbs       Date:  2018-06-05       Impact factor: 5.857

Review 9.  Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier.

Authors:  Stephen B Hladky; Margery A Barrand
Journal:  Fluids Barriers CNS       Date:  2018-10-19

10.  Blood-brain barrier dysfunction and cerebral small vessel disease (arteriolosclerosis) in brains of older people.

Authors:  Leslie R Bridges; Joycelyn Andoh; Andrew J Lawrence; Cheryl H L Khoong; Wayne Poon; Margaret M Esiri; Hugh S Markus; Atticus H Hainsworth
Journal:  J Neuropathol Exp Neurol       Date:  2014-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.